| Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. | |
| | |
MedLine Citation:
|
PMID: 2061979 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To determine whether clinical selection for thrombolytic therapy for acute myocardial infarction results in a skewed population for subsequent adverse cardiovascular events. DESIGN: A comparison of the clinical features of the patients in the Survival and Ventricular Enlargement Study who either had or had not received thrombolytic therapy was conducted in both univariate and multiple logistic regression analyses. SETTING: Hospitalized patients experiencing acute myocardial infarction from 112 broadly representative, private, academic, and government hospitals in the United States and Canada. PATIENTS: All patients in the Survival and Ventricular Enlargement Study had had a recent myocardial infarction (less than 16 days) and had a left ventricular ejection fraction of 40% or less. INTERVENTION: Thrombolytic therapy was administered to 733 patients and was not given to 1498. MAIN OUTCOME MEASURES: The comparisons with respect to use of thrombolytic therapy were formulated after the completion of enrollment and indicated that the majority of patients did not receive thrombolytic therapy. RESULTS: The 1498 (67.1%) patients who did not receive thrombolytic therapy were at higher risk (older age, lower functional capacity, greater likelihood of a history of prior myocardial infarction, angina, diabetes, and hypertension) for subsequent cardiovascular events and, as anticipated, were more likely to have concomitant gastrointestinal and neurological diseases. A multiple logistic regression analysis indicated that older age, prior myocardial infarction, impaired functional status, employment status, diabetes, and neurological diseases were predictors of use of thrombolytic therapy. CONCLUSION: Although the Survival and Ventricular Enlargement Study population was selected for left ventricular dysfunction, the majority of patients who currently are judged clinically as unsuitable for thrombolytic therapy have a higher risk for adverse cardiovascular events. |
| | |
Authors:
|
M A Pfeffer; L A Moy?; E Braunwald; L Basta; E J Brown; T E Cuddy; G R Dagenais; G O Flaker; E M Geltman; B J Gersh |
Related Documents
:
|
3592299 - Myocardial reperfusion by thrombolysis after acute total left main artery occlusion--a ... 12182909 - Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute my... 1430679 - Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarctio... 2496939 - Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarct... 8445189 - Thrombolytic therapy in review. 8170179 - Coronary angioplasty in acute myocardial infarction: primary, immediate adjunctive, res... 3401109 - An introduction to high-resolution ecg recordings of cardiac late potentials. 20876969 - Numerically simulated cardiac exposure to electric current densities induced by taser x... 8780329 - Evolving role of sotalol in the management of ventricular tachyarrhythmias. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: JAMA : the journal of the American Medical Association Volume: 266 ISSN: 0098-7484 ISO Abbreviation: JAMA Publication Date: 1991 Jul 24-31 |
Date Detail:
|
Created Date: 1991-08-06 Completed Date: 1991-08-06 Revised Date: 2010-03-24 |
Medline Journal Info:
|
Nlm Unique ID: 7501160 Medline TA: JAMA Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 528-32 Citation Subset: AIM; IM |
Affiliation:
|
Harvard Medical School, Brigham and Women's Hospital, Boston, Mass 02115. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Captopril
/
therapeutic use* Female Humans Male Middle Aged Myocardial Infarction / drug therapy*, mortality, physiopathology Recurrence Regression Analysis Selection Bias Stroke Volume Thrombolytic Therapy* |
| Chemical | |
Reg. No./Substance:
|
62571-86-2/Captopril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A prospective study of aspirin use and primary prevention of cardiovascular disease in women.
Next Document: Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiologic...